<DOC>
	<DOCNO>NCT01722487</DOCNO>
	<brief_summary>A Randomized , Multicenter , Open-label , Phase 3 Study Bruton 's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil Patients 65 Years Older Treatment-naive Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma .</brief_summary>
	<brief_title>A Multicenter , Open-label , Phase 3 Study Bruton 's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil Patients 65 Years Older With Treatment-naive Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma ( RESONATE™-2 )</brief_title>
	<detailed_description>Study design : This randomize , multicenter , open-label , Phase 3 study design compare safety efficacy Ibrutinib versus Chlorambucil treatment-naive patient 65 year old CLL SLL . Eligible patient randomize 1:1 ratio Treatment Arm A B : - Treatment Arm A : Oral Chlorambucil 0.5 mg/kg Days 1 15 28-day cycle ; dose increase , well tolerate , increment 0.1 mg/kg Day 1 cycle maximum 0.8 mg/kg ; patient receive minimum 3 maximum 12 cycle , absence progressive disease unacceptable toxicity . - Treatment Arm B : Oral Ibrutinib 420 mg/day Randomization stratify Eastern Cooperative Oncology Group ( ECOG ) performance status ( 0,1 versus 2 ) ; presence advance Rai stage ( yes/no ) , advance defined Stages 3-4 ; geographic region : US versus non-US .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>1 . Males females 65 year age great . Patients age 65 70 year age must 1 follow comorbidities may preclude use frontline chemoimmunotherapy fludarabine , cyclophosphamide , rituximab : creatinine clearance &lt; 70 mL/min use CockcroftGault equation platelet count &lt; 100,000/μL hemoglobin &lt; 10 g/dL clinically apparent autoimmune cytopenia ( autoimmune hemolytic anemia immune thrombocytopenia ) ECOG performance score = 1 2 2 . Diagnosis CLL/SLL meet IWCLL diagnostic criterion ( Hallek 2008 ) 3 . Active disease meeting least 1 follow IWCLL criterion ( Hallek 2008 ) require treatment : Evidence progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia Massive , progressive , symptomatic splenomegaly Massive node progressive symptomatic lymphadenopathy Progressive lymphocytosis Autoimmune hemolytic anemia and/or immune thrombocytopenia poorly responsive corticosteroid standard therapy Constitutional symptom 4 . Measurable nodal disease compute tomography ( CT ) 5 . ECOG performance status 02 6 . Life expectancy &gt; 4 month randomization 7 . Adequate hematologic function , define absolute neutrophil count ( ANC ) ≥ 1,000/μL ( independent growth factor support least 7 day prior screen ) platelet count ≥ 50,000/μL ( independent transfusion growth factor support least 7 day prior screen ) 8 . Adequate hepatic function , define serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 2.5 x upper limit normal ( ULN ) , total bilirubin ≤ 1.5 x ULN 9 . Adequate renal function , define estimate creatinine clearance ≥ 30 mL/min use CockcroftGault equation 10 . Willingness receive outpatient treatment , laboratory monitoring , radiological evaluation institution administers study drug entire study 11 . Willingness male patient , sexually active female childbearing potential , use effective barrier method contraception study 3 month follow last dose study drug 12 . Ability provide write informed consent understand comply requirement study 1 . Known involvement central nervous system lymphoma leukemia 2 . History current evidence Richter 's transformation prolymphocytic leukemia 3 . Documentation deletion short arm chromosome 17 : del ( 17p13.1 ) 20 % cell examine pretreatment fluorescence situ hybridization ( FISH ) cytogenetic evaluation 4 . Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenic purpura 5 . Any previous treatment ( chemotherapy , radiotherapy , and/or monoclonal antibody ) intend specifically treat CLL/SLL 6 . Received immunotherapy , vaccine , investigational drug within 4 week prior randomization 7 . Corticosteroid use within 1 week prior first dose study drug , exception inhale , topical , local administration . Patients require systemic steroid daily dos &gt; 20 mg prednisone ( corticosteroid equivalent , see Appendix N ) , administer steroid leukemia control white blood cell ( WBC ) countlowering exclude . 8 . Major surgery within 4 week prior randomization 9 . History prior malignancy , exception following : malignancy treat curative intent evidence active disease present 3 year prior screen felt low risk recurrence treat physician adequately treat nonmelanomatous skin cancer lentigo maligna melanoma without current evidence disease adequately treat cervical carcinoma situ without current evidence disease 10 . Currently active , clinically significant cardiovascular disease history myocardial infarction within 6 month prior randomization 11 . Inability swallow capsule tablet , disease significantly affect gastrointestinal function 12 . Uncontrolled active systemic fungal , bacterial , viral , infection requirement intravenous ( IV ) antibiotics 13 . Known history infection human immunodeficiency virus ( HIV ) 14 . Serologic status reflect active hepatitis B C infection 15 . History stroke intracranial hemorrhage within 6 month prior enrollment 16 . Current lifethreatening illness , medical condition , organsystem dysfunction could compromise patient safety put study risk 17 . Requirement anticoagulation warfarin 18 . Requirement treatment strong CYP3A4/5 and/or CYP2D6 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CLL , SLL</keyword>
</DOC>